Keybanc analyst Jason Celino maintains Udemy (NASDAQ:UDMY) with a Overweight and raises the price target from $15 to $16.
Verve Therapeutics Announced VERVE-101 Awarded Innovation Passport By UK MHRA For Treatment Of Heterozygous Familial Hypercholesterolemia
Verve Therapeutics, Inc. today announced that VERVE-101 has been awarded the Innovation Passport for the treatment of heterozygous familial hypercholesterolemia (HeFH) under the Innovative Licensing and Access Pathway (ILAP) by the Medicines and Healthcare products Regulatory Agency (MHRA), the regulatory body of the United Kingdom (UK).
